Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node
Elena Maiolo1, Silvia Bellesi1, Fabrizia Campana2
1Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Insights
Quantitative flow cytometry reveals lower CD79b expression in aggressive B-cell lymphomas. This analysis of CD79b surface expression in B-cell lymphomas offers insights for guiding therapeutic decisions.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- CD79b is a B-cell-specific antigen vital to the B-cell receptor.
- It is a key therapeutic target in aggressive B-cell lymphomas.
Purpose of the Study:
- To quantitatively analyze CD79b surface expression in aggressive B-cell lymphomas using flow cytometry.
- To compare CD79b expression between lymphoma cases and benign controls.
- To explore the clinical relevance of CD79b expression levels in guiding treatment decisions.
Main Methods:
- Comparative flow cytometry analysis of 127 aggressive B-cell lymphoma cases and benign reactive hyperplasia controls.
- Measurement of CD79b expression percentages and mean fluorescence intensity (MFI).
- Assessment of surface versus intracellular CD79b localization and correlation with clonal light chains.
Main Results:
- Lower CD79b expression percentages and MFI were observed in aggressive B-cell lymphomas compared to controls.
- Significant variability in surface CD79b expression was noted, with 18% showing predominantly intracellular positivity.
- Primary mediastinal B-cell lymphomas had significantly lower surface CD79b expression.
- Higher CD79b expression correlated with older age (>60) and higher R-IPI, factors associated with benefit from anti-CD79b therapy.
Conclusions:
- Quantitative flow cytometry of CD79b surface expression provides clinically relevant data for aggressive B-cell lymphomas.
- CD79b expression analysis can aid in therapeutic decision-making.
- This approach may help identify patients who benefit from targeted anti-CD79b therapies.
Abstract:
Background: CD79b is a B-cell-specific antigen that is crucial to the B-cell receptor and is considered a key target for treatment in aggressive B-cell lymphomas. Methods: While immunohistochemical studies have shown widespread expression of CD79b in mature B-cell-derived lymphomas, flow cytometry allows for precise measurement and differentiation between surface and intracellular localization. Results: In our comparative analysis, we discovered that CD79b expression percentages and mean fluorescence intensity (MFI) were lower in a group of 127 cases of aggressive B-cell lymphomas compared to a control group of benign reactive hyperplasia. We also observed significant variability in the surface expression of CD79b among lymphoma cases, with 18% showing predominantly intracellular positivity. There was a strong correlation between the surface expression of CD79b and clonal light chains. Notably, primary mediastinal B-cell lymphomas exhibited significantly lower surface CD79b expression compared to other lymphoma subtypes (median 0.8% IQR 0-48.5 vs. 80% IQR 24-97, p = 0.0005). Furthermore, patients over 60 years old and those with a higher Revised International Prognostic Index (R-IPI) had significantly higher CD79b expression, both of which are associated with a significant benefit from adding an anti-CD79b drug conjugate to first-line chemotherapy in diffuse large B-cell lymphomas. Conclusions: In conclusion, the quantitative flow cytometric analysis of CD79b surface expression in aggressive B-cell lymphomas provides clinically relevant information, highlighting its potential usefulness in guiding therapeutic decisions.
